COVID-19

Developing new therapies and getting them to patients is long and difficult. During public health emergencies, such as the Covid-19 Pandemic, science must move faster than ever. That is where translational science comes in. Translational science is focused on streamlining the process of moving (“translating”) lab findings into medical practice and treatments to improve health and well-being.

NCATS is supporting research activities spanning the translational science spectrum to address the novel coronavirus 2019 (SARS-CoV-2) and the disease it causes (COVID-19). To accelerate translational research, NCATS has developed research tools, technologies, expertise and collaborative networks that can quickly pivot to address urgent public health issues.

Coronavirus Disease 2019

  • Image

    Columbia University

    The mission of the Irving Institute for Clinical and Translational Research is to advance discoveries, knowledge, and innovation to improve human health across the lifespan for diverse populations in upper Manhattan and around the world. By mobilizing and connecting Columbia University’s researchers, we aim to create a seamless integration of community and academic partnerships. Our commitment to train a multi-faceted workforce, provide vital resources to researchers, and improve the efficiency of research processes, promotes the collaborative team science framework needed to translate research discoveries into effective interventions that address current and future health concerns.

    We provide over 70 different services and programs focused on education and training, seed funding, bioinformatics, biostatistics, clinical research, lifespan research and special populations, regulatory knowledge and bioethics, an off-site community facility and health informatics websites.
  • iTHRIV logo
    -
    University of Virginia

    While much effort has gone into building predictive models of the COVID-19 pandemic, some have argued that early exponential growth combined with the stochastic nature of epidemics make the long-term prediction of contagion trajectories impossible. We conduct two complementary studies to assess model features supporting better long-term predictions. First, we leverage the diverse models

  • iTHRIV logo
    -
    University of Virginia

    Excess cognitive dysfunction has been identified in older adult survivors of COVID-19, compared to other respiratory infections. SARS-CoV-2 may thus adversely impact the brain beyond what the cases of acute stroke, etc. suggest. Unrecognized brain effects of SARS-CoV-2 infection may impact current brain functioning and presage future neurodegeneration and overt neurologic dysfunction. However

  • Melissa Haendel, PhD, professor in the Department of Biochemistry and Molecular Genetics at the University of Colorado School of Medicine, and her team of data scientists have been working at a lightning-fast pace for two years, unlocking some of the mysteries of long COVID. Not only have they been instrumental in the development of the largest national, publicly available HIPAA-limited dataset in

  • UVA-iTHRIV Brain Institute
    -
    University of Virginia

    APPLICATIONS DUE January 8th The global COVID-19 pandemic over the past two years has upset our lives in ways unimaginable before we took to wearing masks, isolating at home, and avoiding contact with family, friends, and colleagues.  We are only now, just contending with the secondary effects of COVID exposures – so-called ‘long-haul COVID’ – but also the effects of deferred regular health check

  • Georgetown University
    Howard University
    MedStar Washington Hospital Center
    George Washington University

    Session recordings are now available from the DC CTSA Consortium's 2022 DC CTSA Spring Regulatory Update & Hot Topics in Clinical and Translational Research. DAY 1 - LASTING IMPACTS OF THE COVID-19 PANDEMIC (APRIL 28, 2022) - Keynote Address - Transcriptome profiling of human blood as a platform for diagnostic biomarker development: Measure broadly, listen carefully - Panel 1: Long-term COVID-19

  • Emory University
    Morehouse School of Medicine

    Racial health disparities impact Coronavirus (COVID-19) infection and fatality rates. Hospitalization rates due to the pandemic among African Americans/Latinx/Hispanics in Georgia have been among the highest in the nation. Sociopolitical determinants, also termed Social Vulnerability (SV), have been identified as central among factors helping to explain the root causes associated with the

  • National COVID Cohort Collaborative (N3C)
    -
    Center for Data to Health
    The N3Community Forum is a place to learn about new COVID-related studies, papers, and opportunities. This event is held on a weekly basis and features one to two presentations from members of the N3C community on selected topics regarding their work with N3C. Each presentation is followed by a discussion session open to participants. Monday, November 14, 2022 at 2pm-3pm PT / 5pm-6pm ET with Sula
  • CLIC

    CLIC has had the honor of serving the CTSA Consortium as your Coordinating Center for the past 5+ years as we transformed the Consortium together. With Consortium members, CLIC launched innovative team science activities – non-traditional Un-meetings and cross-hub, cross-translational level Synergy Papers that have become part of the fabric of the CTSA Program. All hubs participated in one or more

  • CTSC resources have greatly benefitted the ability of many groups to inform policy and medical practice during the COVID pandemic. One example is the highly collaborative interdisciplinary team of Rong Xu, PhD, Director of the Center for Artificial Intelligence and Drug Discovery, David Kaelber, MD, MPH, lead of the CTSC Informatics module and Chief Medical Information Officer in the MetroHealth
  • Re-examining Our Approach to Research: Translational Science Lessons from the Pandemic
    -
    Boston University Medical Campus

    Re-examining Our Approach to Research: Translational Science Lessons from the Pandemic The COVID-19 pandemic laid bare the urgent need to employ research methodologies better suited to more effectively, efficiently and equitably move therapeutics, vaccines and other interventions from bench to bedside to community. Reflecting on lessons learned, this conference will focus on successes and

  • As we head into our third fall of the COVID pandemic, nearly one-third of the U.S. population is still not fully vaccinated, likely due in part to vaccine hesitancy. An Arts and Medicine article recently published in JAMA describes a UR CTSI-supported program that turned to improv theater for help addressing vaccine hesitancy. The program, called the Theater for Vaccine Hesitancy, combined improv
  • CTSI KL2 scholar Carolyn Bramante, MD, MPH, led the nation’s first study on whether metformin, fluvoxamine, and ivermectin, or their combinations could serve as possible treatments to prevent ER visits or hospitalization, as well as Long-COVID. Yesterday, the New England Journal of Medicine published the results of the clinical trial. “Our trial suggests that metformin may reduce the likelihood of

  • Journal of Clinical and Translational Science

    Rapid development and deployment of diagnostic testing for COVID-19 have been a key component of the public health response to the pandemic. Out of necessity, academic and other clinical laboratories developed laboratory testing innovations for COVID-19 to meet clinical testing demands.

  • Journal of Clinical and Translational Science

    Introduction:
    Prior to the COVID pandemic, many CTSAs employed face-to-face interactions to conduct most of their community engagement (CE) activities. During the COVID pandemic, such engagement had to be curtailed and alternatives needed to be formulated. In addition, Community Engaged Research (CEnR) teams refocused their efforts to address this public health crisis.

  • Journal of Clinical and Translational Science

    Introduction:
    COVID-19 altered research in Clinical and Translational Science Award (CTSA) hubs in an unprecedented manner, leading to adjustments for COVID-19 research.

  • Journal of Clinical and Translational Science

    Introduction:
    The COVID-19 pandemic prompted the development and implementation of hundreds of clinical trials across the USA. The Trial Innovation Network (TIN), funded by the National Center for Advancing Translational Sciences, was an established clinical research network that pivoted to respond to the pandemic.

  • Patients previously hospitalized with COVID-19 had a 45% higher risk of heart failure than other hospitalized patients, according to the first national study of its kind, which was co-authored by a University of Arkansas for Medical Sciences (UAMS) researcher. Lead author Husam M. Salah, M.D., at UAMS said the findings reported in Nature Communications also revealed an even higher risk of heart

  • CNBC: Grace McComsey, professor at the School of Medicine, discussed new research into “long COVID” in an effort to understand the mysterious condition. “You’ll be able to access a lot of data, lots of samples on patients that otherwise I can’t do from my own site. It will take me obviously a lot of time and a lot of resources that I don’t have,” McComsey said. Click here to continue reading this
  • Lack of Inclusive Data and Low Trust Remain Barriers to Advancement of Health Equity On Thursday, June 16, 2022, the Clinical and Translational Science Collaborative (CTSC) hosted a REAL (Racial Equity and the Law) Talk webinar, titled Clinical Research Law and Policy, with the Cleveland Metropolitan Bar Association. Gelise Thomas, Assistant Director, Strategic DEI & Health Disparities with the
  • Li’s Bold Hypothesis Helps Generate More Hypotheses in Fittech Xiao Li, PhD, is an Assistant Professor in the Department of Biochemistry and Member of the Center for RNA Science and Therapeutics in the Case School of Medicine and Assistant Professor in the Department of Biochemistry in the Case School of Medicine. Dr. Li combined her passion for science with a love for math and statistics as the
  • With over 10,000 known rare diseases collectively affecting nearly 10% of the population, rare disease patient populations represent unique and varied cohorts for the study of COVID. It can be challenging to identify rare diseases in medical record data but efforts are underway to address those issues. Bryan Laraway and Melissa Haendel presented initial exploratory findings from their work to

  • Grace McComsey, MD, FIDSA, CTSC Principal Investigator, Vice President of Research and Associate Chief Scientific Officer at University Hospitals, and Professor of Pediatrics and Medicine at the CWRU School of Medicine, discussed new research that finds the risks of long COVID symptoms and new onset hypertension, diabetes and heart disease were lower among vaccinated patients with breakthrough

  • The COVID-19 pandemic continues to present considerable public health challenges in the United States and around the globe. One of the most puzzling is why many people who get over an initial and often relatively mild COVID illness later develop new and potentially debilitating symptoms. These symptoms run the gamut including fatigue, shortness of breath, brain fog, anxiety, and gastrointestinal

  • Episode Summary Early in the pandemic, Claire Decoteau, Iván Arenas their robust team of interdisciplinary researchers began to interview Black, Latinx, and white residents of three Chicago neighborhoods in order to explore how the pandemic has impacted different communities. Drawing on over 150 interviews with residents and policy makers, the team found that while COVID-19 has been treated as a
  • A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept — drugs widely used to treat certain autoimmune diseases — did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths. Some COVID-19 patients experience an immune

  • SDoH are the non-clinical covariates of how people live, grow, learn and age and relates to how people manage stressors or prevent worsening health outcomes. Progressively, data about patient-level SDoH are collected using clinical screening tools for social needs and social risk factors. CD2H has led multiple SDoH synergistic initiatives relating to overall improvement of SDoH encoding and

  • Translational Science Seminar - Center for Biodevices: Collaboration Across Disciplines - June 8 noon to 1:00 pm
    -
    Pennsylvania State Univ Hershey Med Ctr

    In this seminar, Mary Frecker, PhD, and Greg Lewis, PhD, director and associate director of Penn State Center for Biodevices, will describe the Center’s approach toward fostering multidisciplinary research collaborations and the recommendations of a University-wide panel they have hosted on this topic. This seminar is for researchers interested in learning about cross-campus interdisciplinary

  • Washington University School of Medicine in St. Louis has received a $61 million grant from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) to support the infrastructure for developing and carrying out biomedical research studies. The funding supports Washington University’s Institute of Clinical and Translational Sciences (ICTS), which was

  • Congratulations to Sara Auld, MD, MSc, who received the Albert E. Levy Award for Excellence in Scientific Research, junior faculty at Emory University. “I am so grateful for the wonderful colleagues and mentors I have had the pleasure of working with over the last several years,” says Dr. Auld. “As the saying goes, ‘chance favors the prepared,’ and my MSCR training allowed me to be prepared to